Skip to main content

Revolutionizing Vitiligo (ReV) Conference

Revolutionizing Vitiligo
Preliminary Agenda

Saturday, June 8, 2024

5:00 pm - 8:00 pm (CT)

Registration

7:30 pm - 9:00 pm (CT)

Posters and Exhibits Reception

Sunday, June 9, 2024

8:15 am - 8:45 am (CT)

Breakfast and Keynote
Microbiome in Vitiligo

CAROLYN LE POOLE, PHD

Part 1: Therapeutics

Invited Faculty

8:50 AM (CT)

Current Pathogenesis of Vitiligo and Models of Disease

Victor Huang, MD

9:10 AM (CT)

Topical Therapeutics for Vitiligo

Nanette Silverberg, MD

9:30 AM (CT)

Currently Available Systemic Therapies in Vitiligo

Victor Huang, MD

9:50 AM (CT)

Systemic Agents for Vitiligo: The Relationship of Therapies to Disease Pathogenesis

David Rosmarin, MD

10:10 AM (CT)

Break/Q&A

Part 2: Emerging Therapies

10:20 AM (CT)

Whats New in Development for Vitiligo

David Rosmarin, MD

10:40 AM (CT)

Recent Advances in Devices for Vitiligo

Karan Lal, DO, MS

11:00 AM (CT)

Q&A

All Speakers

Part 3: Setting Up a Vitiligo Clinic: Lessons from the Experts

11:15 AM (CT)

Excellence in Vitiligo Clinical Practice

Nanette Silverberg, MD

11:35 am (CT)

Clinical Pearls for a Vitiligo Practice

All Speakers

11:55 AM (CT)

Q&A

All Speakers

Monday, June 10, 2024

1:30 pm - 4:00 pm (CT)

1:30 PM Opening Remarks Jonathan Silverberg, MD, PhD, MPH
1:35 PM Long-term Safety and Efficacy of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis: A 52-week, Phase 3, Open-Label Extension Trial Melinda Gooderham, MSc,
MD, FRCPC
1:43 PM Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial Robert Bissonette, MD, FRCPC
1:51 PM Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis Robert Bissonette, MD, FRCPC
2:00 PM Positive patient-reported outcomes following treatment of stable vitiligo with autologous skin cell suspension transplantation prepared by a point-of-care cell harvesting device Nanette Silverberg MD
2:08 PM Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS) Jonathan Silverberg, MD, PhD, MPH
2:16 PM Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study Jonathan Silverberg, MD, PhD, MPH
2:24 PM Establishing a Patient-Centered Definition of Atopic Dermatitis Flare: Insights from a Modified eDelphi Study Wendy Smith Begolka
2:32 PM United States Prevalence of Atopic Dermatitis in Adults by Race and Ethnicity Raj Chovatiya, MD, PhD, MSCi
2:38 PM Impact of amlitelimab (an anti-OX40 Ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe atopic dermatitis Raj Chovatiya, MD, PhD, MSCi
2:46 PM Patient Preferences for Atopic Dermatitis Treatment Profiles: Results from A Discrete Choice Experiment Raj Chovatiya, MD, PhD, MSCi
2:52 PM Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years Raj Chovatiya, MD, PhD, MSCi
2:58 PM The TCS/TCI-free rate remains high and stable while on lebrikizumab for treatment of moderate-to-severe atopic dermatitis over 1 year Raj Chovatiya, MD, PhD, MSCi
3:04 PM The heterogeneous characteristics of itch vary by atopic dermatitis severity and differentially impact quality of life in children and adults: A prospective cohort study Brandon Ansbro. BA
3:12 PM Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study Jonathan Silverberg, MD, PhD, MPH
3:20 PM EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations Jonathan Silverberg, MD, PhD, MPH
3:28 PM Upadacitinib dose alterations in adolescent and adult patients with atopic dermatitis: a real-world multicenter retrospective review Vimal Prajapati, MD
3:46 PM Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies Vimal Prajapati, MD
3:54 PM Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (SEASIDE CHINA) Zhiange Zhang, MD
4:04 PM Treatment of conjunctivitis in dupilumab-treated patients with atopic dermatitis: an observational study Penny A. Asbell, MD, FACS, MBA, FARVO
4:12 PM Cost per Responder in Brazil (EASI-75, EASI90 and ∆NRS ≥4) of biologics and JAK inhibitors Based on a Network-Meta-Analysis of Therapies for Atopic Dermatitis Guillherme Muzy, MD
4:20 PM Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: A post hoc analysis of ARCADIA 1 and 2 data Jonathan Silverberg, MD, PhD, MPH
4:28 PM Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Results of an Open-label, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up) Jonathan Silverberg, MD, PhD, MPH
4:36 PM Clinical Efficacy, Safety, and Pharmacokinetic Profile of Bosakitug (BSI-045B), an Anti-Thymic Stromal Lymphopoietin (TSLP) mAb in a Phase 2 Study of Moderate and Severe Atopic Dermatitis Subjects Jennifer Parish, MD

(Agenda subject to change)